NCT02779257

Pasireotide Treatment for Neuroendocrine Tumor

Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Maryland, Baltimore · Academic / Other
• Sex: Male
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.

Conditions

• Gastro-enteropancreatic Neuroendocrine Tumor

Interventions

Type	Name	Description
DRUG	Pasireotide	Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
DRUG	Diazoxide	Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.

Timeline

• Start date: 2016-04-01
• Primary completion: 2016-06-01
• Completion: 2016-06-01
• First posted: 2016-05-20
• Last updated: 2022-03-04